Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | MMP3 | P08254 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7190843 | 0.98 | CYP1A2 (0.65) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL3267877 | 0.91 | HDAC1 (0.63) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL4411547 | 0.90 | MMP3 (0.54) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL6189108 | 0.90 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| Hydrochloric Acid SCHEMBL5639911 | 0.89 | HDAC1 (0.61) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| Isophthalic Acid SCHEMBL17394551 | 0.88 | SMN1; SMN2 (0.60) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL4411183 | 0.87 | KDM4E (0.58) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL4412344 | 0.85 | MMP3 (0.63) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL4412300 | 0.85 | MMP3 (0.50) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL4773749 | 0.83 | MMP3 (0.81) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-54077655-A | — | — | None | — | — | JP | disclosed |
| CN-108884282-B | Polyethylene and molded article thereof | 日本聚乙烯株式会社 | 2021-06-08 | — | — | CN | disclosed |
| CN-105121035-B | The manufacture method of the products formed of organosilane crosslinked polyethylene resin, the manufacture method and its manufacture device of bar-shaped products formed | 三菱电机株式会社 | 2017-11-14 | — | — | CN | disclosed |
| CN-105121035-A | Production method for molded article of silane crosslinked polyethylene resin, production method for molded rod, and production device for same | MITSUBISHI ELECTRIC CORP | 2015-12-02 | — | — | CN | disclosed |
| US-7638565-B2 | Polyacetal resin composition | POLYPLASTICS CO., LTD. (JP) | 2009-12-29 | — | — | US | disclosed |
| US-20070054998-A1 | Polyacetal resin composition | POLYPLASTICS CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1686156-A1 | POLYACETAL RESIN COMPOSITION | Polyplastics Co., Ltd. (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-6586437-B2 | Administering (S)-hydroxynefazodone or its salt for therapy of psychosis | SEPRACOR INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030083338-A1 | Compositions and methods for management of serotonin-mediated disorders | SEPRACOR, INC. | 2003-05-01 | — | — | US | disclosed |
| US-6469008-B2 | THERAPY OF PSYCHOSIS IN A HUMAN COMPRISING ADMINISTERING (R)-HYDROXYNEFAZODONE OR A PHARMACEUTICALLY ACCEPTABLE SALT | SEPRACOR INC. | 2002-10-22 | — | — | US | disclosed |
| WO-2002069951-A2 | COMPOSITION CONTAINING A NEFAZONOID SUCH AS NEFAZODONE AND A SEROTONIN-INHIBITOR SUCH AS FLUOXETINE | SEPRACOR INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020077326-A1 | Administering (S)-hydroxynefazodone or its salt for therapy of psychosis | SEPRACOR INC. | 2002-06-20 | — | — | US | disclosed |
| US-20020058675-A1 | (R)-hydroxynefazodone antipsychotic therapy | SEPRACOR INC. (US) | 2002-05-16 | — | — | US | disclosed |
| US-5900485-A | Methods for the manufacture of neofazodone | APOTEX, INC. (CA) | 1999-05-04 | — | — | US | disclosed |
| US-4575555-A | ANTIDEPRESSANTS | MEAD JOHNSON & COMPANY (US) | 1986-03-11 | — | — | US | disclosed |
| US-4487773-A | ANTISEROTONINE AGENTS | MEAD JOHNSON & COMPANY (US) | 1984-12-11 | — | — | US | disclosed |
| JP-S5477655-A | CROSSLINKING OF POLYOLEFIN AND PRODUCTION OF CROSSLINKED POLYOLEFIN INSULATED WIRES | HITACHI CABLE LTD | 1979-06-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077326-A1 | Administering (S)-hydroxynefazodone or its salt for therapy of psychosis | SLC6A3, SLC6A2, SLC6A4 | CYP1A2 1827/4885CYP3A4 2535/4885CYP2C19 1703/4885 |
| US-20030083338-A1 | Compositions and methods for management of serotonin-mediated disorders | HTR5A, TPH1, HTR4 | CYP1A2 305/4885CYP3A4 235/4885CYP2C19 159/4885 |
| US-20020058675-A1 | (R)-hydroxynefazodone antipsychotic therapy | GABRE, GRIN2A, HTR3E | CYP1A2 1090/4885CYP3A4 1745/4885CYP2C19 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.